CD44 Antibody (clone BU52, Azide-free)
Mouse Monoclonal Antibody
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Application
| IHC-P, FC |
---|---|
Primary Accession | P16070 |
Other Accession | 960 |
Reactivity | Human |
Host | Mouse |
Clonality | Monoclonal |
Isotype | IgG1 |
Clone Names | BU52 |
Calculated MW | 81538 Da |
Dilution | IHC-P (10 µg/ml), |
Gene ID | 960 |
---|---|
Other Names | CD44, CDW44, CD44 antigen, Cell surface glycoprotein CD44, CSPG8, ECMR-III, Epican, HUTCH-I, LHR, MDU2, MC56, MIC4, Hermes antigen, Hyaluronate receptor, Phagocytic glycoprotein 1, PGP-1, PGP-I, Pgp1, Phagocytic glycoprotein I, MDU3, CD44R, HCELL, He ... |
Target/Specificity | Epitope 1 of the CD44 molecule. |
Reconstitution & Storage | 50 mM sodium phosphate, pH 7.5, 100 mM potassium chloride, 150 mM sodium chloride. Store at +4°C. Do not freeze. Open under aseptic conditions. |
Precautions | CD44 Antibody (clone BU52, Azide-free) is for research use only and not for use in diagnostic or therapeutic procedures. |
Name | CD44 |
---|---|
Synonyms | LHR, MDU2, MDU3, MIC4 |
Function | Cell-surface receptor that plays a role in cell-cell interactions, cell adhesion and migration, helping them to sense and respond to changes in the tissue microenvironment (PubMed:16541107, PubMed:19703720, PubMed:22726066). Participates thereby in a wide variety of cellular functions including the activation, recirculation and homing of T-lymphocytes, hematopoiesis, inflammation and response to bacterial infection (PubMed:7528188). Engages, through its ectodomain, extracellular matrix components such as hyaluronan/HA, collagen, growth factors, cytokines or proteases and serves as a platform for signal transduction by assembling, via its cytoplasmic domain, protein complexes containing receptor kinases and membrane proteases (PubMed:18757307, PubMed:23589287). Such effectors include PKN2, the RhoGTPases RAC1 and RHOA, Rho-kinases and phospholipase C that coordinate signaling pathways promoting calcium mobilization and actin-mediated cytoskeleton reorganization essential for cell migration and adhesion (PubMed:15123640). |
Cellular Location | Cell membrane; Single-pass type I membrane protein. Cell projection, microvillus {ECO:0000250|UniProtKB:P15379}. Secreted Note=Colocalizes with actin in membrane protrusions at wounding edges Co-localizes with RDX, EZR and MSN in microvilli. Localizes to cholesterol-rich membrane-bound lipid raft domains {ECO:0000250|UniProtKB:P15379, ECO:0000269|PubMed:23589287} |
Tissue Location | Detected in fibroblasts and urine (at protein level) (PubMed:25326458, PubMed:36213313, PubMed:37453717). Detected in placenta (at protein level) (PubMed:32337544). Isoform 10 (epithelial isoform) is expressed by cells of epithelium and highly expressed by carcinomas. Expression is repressed in neuroblastoma cells |
Volume | 50 µl |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
Receptor for hyaluronic acid (HA). Mediates cell-cell and cell-matrix interactions through its affinity for HA, and possibly also through its affinity for other ligands such as osteopontin, collagens, and matrix metalloproteinases (MMPs). Adhesion with HA plays an important role in cell migration, tumor growth and progression. In cancer cells, may play an important role in invadopodia formation. Also involved in lymphocyte activation, recirculation and homing, and in hematopoiesis. Altered expression or dysfunction causes numerous pathogenic phenotypes. Great protein heterogeneity due to numerous alternative splicing and post-translational modification events.
References
Stamenkovic I.,et al.Cell 56:1057-1062(1989).
Harn H.-J.,et al.Biochem. Biophys. Res. Commun. 178:1127-1134(1991).
Stamenkovic I.,et al.EMBO J. 10:343-348(1991).
Dougherty G.J.,et al.J. Exp. Med. 174:1-5(1991).
Kugelman L.C.,et al.J. Invest. Dermatol. 99:886-891(1992).
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.